



Edgar Filing: CTI BIOPHARMA CORP - Form 4

Common Stock	09/22/2014	<u>S<sup>(1)</sup></u>	300	D	\$ 2.54	538,404	D
Common Stock	09/22/2014	<u>S<sup>(1)</sup></u>	300	D	\$ 2.55	538,104	D
Common Stock	09/22/2014	<u>S<sup>(1)</sup></u>	981	D	\$ 2.56	537,123	D
Common Stock	09/22/2014	<u>S<sup>(1)</sup></u>	3,000	D	\$ 2.57	534,123	D
Common Stock	09/22/2014	<u>S<sup>(1)</sup></u>	27,400	D	\$ 2.58	506,723	D
Common Stock	09/22/2014	<u>S<sup>(1)</sup></u>	2,793	D	\$ 2.59	503,930	D
Common Stock	09/22/2014	<u>S<sup>(1)</sup></u>	3,901	D	\$ 2.6	500,029	D
Common Stock	09/22/2014	<u>S<sup>(1)</sup></u>	1,408	D	\$ 2.61	498,621	D
Common Stock	09/22/2014	<u>S<sup>(1)</sup></u>	2,635	D	\$ 2.62	495,986	D
Common Stock	09/22/2014	<u>S<sup>(1)</sup></u>	2,200	D	\$ 2.63	493,786	D
Common Stock	09/23/2014	<u>S<sup>(1)</sup></u>	3,900	D	\$ 2.5	489,886	D
Common Stock	09/23/2014	<u>S<sup>(1)</sup></u>	15,728	D	\$ 2.51	474,158	D
Common Stock	09/23/2014	<u>S<sup>(1)</sup></u>	722	D	\$ 2.52	473,436	D
Common Stock	09/23/2014	<u>S<sup>(1)</sup></u>	2,600	D	\$ 2.53	470,836	D
Common Stock	09/23/2014	<u>S<sup>(1)</sup></u>	3,300	D	\$ 2.54	467,536	D
Common Stock	09/23/2014	<u>S<sup>(1)</sup></u>	14,118	D	\$ 2.55	453,418	D
Common Stock	09/23/2014	<u>S<sup>(1)</sup></u>	9,250	D	\$ 2.56	444,168	D
Common Stock	09/23/2014	<u>S<sup>(1)</sup></u>	600	D	\$ 2.57	443,568	D
Common Stock	09/23/2014	<u>S<sup>(1)</sup></u>	1,600	D	\$ 2.58	441,968	D

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

**Persons who respond to the collection of information contained in this form are not**

SEC 1474  
(9-02)

required to respond unless the form displays a currently valid OMB control number.

**Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned**  
(e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)	7. Title and Amount of Underlying Securities (Instr. 3 and 4)	8. Price of Derivative Security (Instr. 5)	9. Number of Derivative Securities Owned Following Transaction (Instr. 6)
				Code	V (A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

## Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
Plunkett Matthew 3101 WESTERN AVENUE, SUITE 600 SEATTLE, WA 98121			EVP, Corporate Development	

## Signatures

Louis A. Bianco Attorney-in-fact For: Matthew Plunkett  
09/24/2014

\_\_Signature of Reporting Person Date

## Explanation of Responses:

- \* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

(1) The sale was effected pursuant to a Rule 10b5-1 trading plan.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.